Delivery Order SPE2DP20D0002-SPE2DP25F6735

Award Date 5/12/25
Potential Completion Date 5/20/25
Potential Value $826K
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $317,609.46 Delivery Order contract for the supply of Adenovirus Type 4 vaccines. This order falls under DLA Troop Support Medical's larger portfolio of contracts supporting military immunization programs. The contract has a firm fixed-price, with a completion date of June 25, 2024. Teva Pharmaceuticals USA, Inc. is a major supplier of critical drugs and...
This is a firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $330,313.86, is for the delivery of Adenovirus Type 4 vaccines to support military immunization programs. Teva Pharmaceuticals USA, Inc. is a major supplier of critical pharmaceutical products to federal agencies, including the Department of Veterans Affairs...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $825,784.65, is for the delivery of Adenovirus Type 4 vaccine, which supports military immunization programs. Teva Pharmaceuticals USA, Inc. is a major supplier of critical medical products to federal agencies, including the Department of Veterans Affairs (VA), Department...
The Defense Logistics Agency (DLA) Troop Support Medical has awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $476,414.19 firm-fixed-price delivery order to provide Adenovirus Type 4 vaccine. The contract has a completion date of February 27, 2024. Teva Pharmaceuticals USA, Inc. is a subsidiary of the global pharmaceutical company Teva Pharmaceutical Industries Ltd. and has been awarded numerous prime contracts by federal agencies such as the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $165,156.93, is for the delivery of Adenovirus Type 4 vaccine, which supports military immunization programs. The contract is a firm-fixed-price delivery order with a performance period through March 25, 2025. Teva Pharmaceuticals USA, Inc. is the prime contractor, and there are no...
This federal contract award, valued at $317,609.46, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc. for the delivery of the Adenovirus Type 4 vaccine. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit pharmaceutical manufacturer that serves as a major supplier of critical drug products to various U.S. federal government agencies, including the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of...
The U.S. government agency Defense Logistics Agency (DLA) Troop Support Medical awarded a $158,804.73 firm-fixed-price delivery order contract to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This delivery order is part of a larger contract vehicle, and Teva has received multiple prior delivery orders for this vaccine to support military immunization programs. Teva also holds several significant Indefinite...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a $317,609.46 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide Adenovirus Type 4 vaccines. This order has a completion date of January 30, 2024 and is not a set-aside contract. Teva Pharmaceuticals USA, Inc. provides critical pharmaceutical products to federal agencies like the Department of Veterans Affairs (VA), Department of Defense (DOD),...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The $495,470.79 contract is for the delivery of Adenovirus Type 4 vaccine, which supports military immunization programs. Teva Pharmaceuticals USA, Inc. is a key supplier to federal healthcare programs, providing essential pharmaceutical products to agencies such as the Department of Veterans...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,270,437.84 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. to provide Adenovirus Type 4 vaccines. Teva is a large, foreign-owned pharmaceutical manufacturer that has fulfilled numerous federal contracts for critical medical products, including vaccines, antiviral medications, respiratory treatments, and multiple sclerosis drugs for agencies such as the Department of Veterans Affairs (VA) and Department of...
  • SPE2DP20D0002
    Indefinite Delivery Contract
  • SPE2DP20D0002-SPE2DP25F6735
    Delivery Order

This firm-fixed-price delivery order contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The $825,784.65 contract is for the delivery of Adenovirus Type 4 vaccines, which are critical medical products for military immunization programs. Teva is a key supplier to federal healthcare agencies, including the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons, and Indian Health Service. The contract has an ultimate completion date of May 20, 2025 and was awarded on May 12, 2025. Teva has also been awarded two significant Indefinite Delivery Contracts (IDCs) by the VA and DLA, further demonstrating its strategic role in maintaining a stable and reliable supply of critical pharmaceutical products for federal healthcare programs.

Generated 8/17/25, 12:59 AM